# **Research Letter**



# Bao-Gan-Xiao-Zhi-Wan Treatment Attenuates Methioninecholine-deficient Diet-induced Metabolic Dysfunctionassociated Steatohepatitis in Rats by Modulating the NF-κB Signal Pathway and Autophagy

Liming Zhou<sup>1,2</sup>, Xiaobin Zeng<sup>3,4</sup>, Xiaofang Wei<sup>3,5</sup>, Wanying Shen<sup>3,5</sup>, Jie Yao<sup>3</sup>, Weigang Wu<sup>1,3</sup>, Lanlan Ge<sup>3,4\*</sup><sup>(1)</sup> and Boping Zhou<sup>1,3\*</sup><sup>(2)</sup>

<sup>1</sup>The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, Guangdong, China; <sup>2</sup>Department of Endocrinology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Health Science Center of Shenzhen University, Shenzhen, Guangdong, China; <sup>3</sup>Center Lab of Longhua Branch and Department of Infectious Disease, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University), Shenzhen, Guangdong, China; <sup>4</sup>Department of Pathology (Longhua Branch), Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University), Shenzhen, Guangdong, China; <sup>5</sup>College of Pharmacy, Gansu University of Chinese Medicine, Lanzhou, Gansu, China

Received: January 25, 2024 | Revised: March 26, 2024 | Accepted: April 03, 2024 | Published online: April 16, 2024

**Citation of this article:** Zhou L, Zeng X, Wei X, Shen W, Yao J, Wu W, *et al*. Bao-Gan-Xiao-Zhi-Wan Treatment Attenuates Methionine-choline-deficient Diet-induced Metabolic Dysfunction-associated Steatohepatitis in Rats by Modulating the NF- $\kappa$ B Signal Pathway and Autophagy. J Clin Transl Hepatol 2024;12(6):607–611. doi: 10.14218/JCTH.2024.00031.

Non-alcoholic fatty liver disease (NAFLD) is a condition involving the accumulation of liver fat in excess of 5–10% of its weight after excluding excessive alcohol intake and any other causes of liver disease or steatosis.1 NAFLD has increased with the occurrence of obesity, diabetes, and metabolic syndrome, due to which an international consensus of experts proposed renaming it metabolic dysfunction-associated fatty liver disease (MAFLD).<sup>2,3</sup> Liver steatosis and steatohepatitis, followed by advanced fibrosis, cirrhosis, and hepatocellular carcinoma, are pathological changes associated with MAFLD.<sup>4</sup> One of the disease's progressive phases is metabolic dysfunction-associated steatohepatitis (MASH), which is characterized by steatosis with ballooning and inflammation.<sup>5</sup> Approximately a quarter of the world's population has MAFLD, and a quarter of those patients have MASH.<sup>6</sup> Despite its clinical significance, MASH has limited treatment options. Clinical drugs for MASH treatment are not yet available, necessitating the development of safe and effective MASH drugs and additional research.

Yinchenhao Decoction, which was introduced in Zhang Zhongjing's "*Treatise on Febrile Diseases*", is a traditional Chinese medicine prescribed for liver diseases.<sup>7</sup> According

to traditional Chinese medical beliefs, the main pathogenesis of MASH is dampness and heat stagnation. Si-Wei-Qing-Gan-Tang (SWQGT) is a folk prescription formulated from the Yinchenhao decoction and is used for clearing heat and dispelling dampness.<sup>8</sup> The findings of our previous study showed that the effects of SWQGT are good for relieving MASH but are not satisfactory for reducing serum transaminases.<sup>8</sup> Therefore, the improved formula, Bao-Gan-Xiao-Zhi-Wan (BGXZW), was studied. BGXZW consists of seven Chinese herbs: *Artemisia capillaris* Thunb, *Hedyotis diffusa* Willd, *Gardenia jasminoides* Ellis, *Taxillus sutchuenensis* (Lecomte) Danser, *Salvia miltiorrhiza* Bunge, *Glycyrrhiza uralensis* Fisch, and *Rheum palmatum* L (Supplementary Fig. 1A). The HPLC fingerprint of BGXZW (Supplementary Fig. 1B) shows that the main compounds were derived from Danshen, Yinchen, and Gancao.

In the present study, we established a rat model of MASH by feeding rats a methionine-choline-deficiency (MCD) diet. The methodology is described in detail in Supplementary File 1. As shown in Supplementary Table 1, the body weight of the rats in the model group was significantly lower (p < 0.05) than those of the rats in the control group on Day 28. This loss of body weight was not reversed by BGXZW or SWQGT. The main reason for this observation was that the average food intake levels were lower for the model and drug rat groups than for the control rat group. In addition, the liver index was dramatically higher for the rats in the model group than for the rats in the control group (p < 0.001), and BGXZW treatment reversed this elevation (p < 0.05) (Supplementary Fig. 2B). The histological characteristics of the heart, spleen, lung, and kidney were observed. No significant difference was found in the morphological characteristics of the rats in each group (Supplementary Fig. 2F), indicating that BGXZW relieved the liver damage caused by the MCD diet.

Similar to SWQGT, administering BGXZW had certain effects on blood lipid levels (TC, TG, and LDL-c) (Fig. 1A-C).

<sup>\*</sup>Correspondence to: Lanlan Ge and Boping Zhou, Center Lab of Longhua Branch and Department of Infectious Disease, Shenzhen People's Hospital, Shenzhen, Guangdong 518020, China. ORCID: https://orcid.org/0000-0003-4638-3185 (LG) and https://orcid.org/0000-0001-6676-1900 (BZ). Tel/Fax: +86-755-27745118-63058, Email: gelanlan4710@163.com (LG) and zhoubp@ hotmail.com (BZ)

Copyright: © 2024 The Author(s). This article has been published under the terms of Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided. "This article has been published in *Journal of Clinical and Translational Hepatology* at https://doi.org/10.14218/JCTH.2024.00031 and can also be viewed on the Journal's website at http://www.jcthnet.com".



Zhou L. et al: Bao-Gan-Xiao-Zhi-Wan treatment attenuates MASH

**Fig. 1. Effect of BGXZW and SWQGT on rats in each group.** (A) TC, (B) serum TG, (C) serum LDL-c, (D) serum ALT, (E) serum AST, (F) liver ALT, (G) liver AST, (H) liver morphology, (I) HE stained sections ( $200\times$ ). Results are expressed as the mean±SEM (n=8 rats in each group). #p<0.05 compared with the control group, # $#^{p}$ <0.001 compared with the control group, \*p<0.05 compared with model group, \*p<0.01 compared with the model group, Ctrl group, MCS diet and fed with pure water; group; Model group, MCD diet and fed with pure water; PPC group, MCD diet and fed with PPC (120 mg/kg/d); BG-L group, MCD diet and fed with high-dose BGXZW (1.67 g/kg/d); BG-H group, MCD diet and fed with high-dose BGXZW (5 g/kg/d); SW group, MCD diet and fed with SWQGT (3 g/kg/d); MCD, methionine choline deficiency; MCS, methionine and choline-sufficient; BGXZW, Bao-Gan-Xiao-Zhi-Wan; SWQGT, Si-Wei-Qing-Gan-Tang; TC, total cholesterol; TG, triglyceride; LDL-c, low-density lipoprotein cholesterol; ALT, alanine aminotransferase; AST, aspartate transaminase; BGXZW, Bao-Gan-Xiao-Zhi-Wan; H&E, hematoxii and eosin.

As ALT and AST are two important indicators for evaluating liver damage, we detected the serum and liver indicators of the MCD diet-fed rats (Fig. 1D–G). Results showed that the elevated ALT and AST levels caused by the MCD diet were remarkably reversed by BGXZW. In general, BGXZW was found to significantly increase blood fat levels, especially reduce the level of transaminase, better than SWQGT.

The morphology of the liver tissue in each rat group is shown in Figure 1H. Intuitive observations with the naked eye revealed that the rat livers in the control group were dark red, with normal capsules and clear edges, and they were elastic to the touch. In contrast, the rat livers in the model group were enlarged, soft, and gravish white, with tense capsules and blunt edges. Further, the rat livers in the BG-H and SW groups were superior to those in the model group in terms of shape, size, color, and touch. H&E staining revealed that the MCD diet induced macrovesicular steatosis and inflammation in the livers of the rats (Fig. 1I). Numerous fat vacuoles were observed in the liver tissue of the model group rats, and adjacent cells were crowded together, resulting in unclear cell boundaries. The nucleus was located on one side of the cell, and the structure of the liver cord was blurred. These conditions of liver fat accumulation caused by the MCD diet were attenuated by treatment with PPC, BGX-ZW, and SWQGT. However, liver fat percentage alone does not reflect the degree of liver inflammation, liver damage,

or tissue fibrosis. Therefore, the NAFLD activity score (NAS) is generally used in clinical and preclinical studies. A total NAS score greater than 5 is indicative of MASH rather than simple fatty liver disease.<sup>9</sup> Pathologists obtain the total NAS score by summing the scores of three parameters: steatosis (0–3 points), inflammation (0–3 points), and ballooning (0–2 points).<sup>9</sup> Accordingly, we selected eight visual fields for scoring in each group; the scores and scoring specification are shown in Tables 1 and 2. The NAS score of the model group was  $6.375\pm1.19$ , indicating that these rats suffered from typical MASH. In contrast, the rats in the PPC, BG, and SW groups had improved scores of less than 5. These results proved that BGXZW and SWQGT ameliorated the MCD-induced abnormal lipid accumulation and inflammatory injury in the livers of rats.

Nuclear factor- $\kappa$ B (NF- $\kappa$ B) is a transcription factor that plays a vital role in regulating the inflammatory response.<sup>10</sup> To explore the underlying mechanism, we first examined the levels of NF- $\kappa$ B and downstream inflammatory factors. BGX-ZW treatment resulted in a large decrease in the levels of NF- $\kappa$ B, IL-1 $\beta$ , COX2, and iNOS (Fig. 2A, C-E). These experimental results confirmed that the MCD diet activated the NF- $\kappa$ B pathway and that BGXZW played an anti-inflammatory role in the liver by downregulating NF- $\kappa$ B and inhibiting the release of inflammatory factors.

Previous studies have shown that SWQGT inhibits the

Zhou L. et al: Bao-Gan-Xiao-Zhi-Wan treatment attenuates MASH

Choung	NAS Score					
Groups	Steatosis	Inflammation	Ballooning	Total		
Ctrl group	0	0	0	0		
Model group	2.75±0.46 <sup>###</sup>	1.875±0.83 <sup>###</sup>	1.75±0.46 <sup>###</sup>	6.375±1.19 <sup>###</sup>		
PPC group	1.625±0.52***	1.5±0.76	0.625±0.52***	3.75±1.04***		
BG-L group	1.875±0.64**	$1.5 \pm 0.76$	0.625±0.52***	4±1.30***		
BG-H group	1.625±0.52***	1.375±0.74	0.5±0.53	3.5±1.07***		
SW group	1.75±0.70**	1.5±0.76	0.625±0.52***	3.875±0.99***		

Table 1.	Effects of BGXZV	and PPC on NAFLI	Activity Score	(NAS) in MCD	diet-fed rats
----------	------------------	------------------	----------------	--------------	---------------

Results are expressed as the mean±SD (n=8).  $^{##}p<0.001$  compared with the control group,  $^{**}p<0.01$  compared with the model group, MCD diet and fed with pure water; group; Model group, MCD diet and fed with pure water; PPC group, MCD diet and fed with PPC (120 mg/kg/d); BG-L group, MCD diet and fed with low-dose BGXZW (1.67 g/kg/d); BG-H group, MCD diet and fed with high-dose BGXZW (5 g/kg/d); SW group, MCD diet and fed with SWQGT (3 g/kg/d). MCD, methionine choline deficiency; MCS, methionine and choline-sufficient; BGXZW, Bao-Gan-Xiao-Zhi-Wan; SWQGT, Si-Wei-Qing-Gan-Tang.

mechanistic target of rapamycin (mTOR) and activates autophagy in the livers of MCD diet-fed rats.<sup>8</sup> Thus, we also examined autophagy-associated proteins and genes. ULK1 is a key protein for autophagy initiation, p62 is an autophagic substrate usually used to evaluate the level of autophagy flux, and LC3II is a marker of autophagosome formation; therefore, these three proteins are considered key proteins in the regulation of autophagy.<sup>11,12</sup> As shown in Figure 2B, the rats in the BGXZW treatment group had decreased levels of p-mTOR and p62 proteins and enhanced levels of p-ULK1 and LC3II proteins. In addition, the rats in the BG-L and BG-H groups had reduced RNA levels of mTOR (p<0.01), compared to the rats in the model group (Fig. 2F). Furthermore, compared to the model group, the BG-H group exhibited increased RNA levels of LC3 (p<0.05), while the BG-L group showed no significant difference (Fig. 2G). In general, BGXZW inhibited mTOR-activated autophagy in the livers of the MCD diet-fed rats.

In sum, BGXZW effectively reduced serum ALT and AST levels, thus showing that the improved Chinese herbal formula is successful in alleviating MASH. The results of the preliminary molecular mechanism study confirmed that

Table 2. Scoring specification

Classify	Histological features	Score
Healthy	<u>100 pm</u>	Hepatocytes are nicely arranged and densely packed.
Steatosis		Steatosis score represents the percentage of lipid droplets present in each field of view, 0 point, <5%; 1 point, <33%; 2 point, 34–66%; 3 point, >66 %.
Inflammation	<u>100 µm</u>	Inflammation score represents the number of inflammatory cell clusters (1 cluster 1 foci), 0 point, 0 foci; 1 point,1–2 foci; 2 point, 3–4 foci; 3 point, >4 foci.
Ballooning	<u>10 pn</u>	Ballooning score is indicative of the number of hepatocytes that have altered cell structure due to excess lipid accumulation, 0 point, none; 1 point, few; 2 point, many.



### Zhou L. et al: Bao-Gan-Xiao-Zhi-Wan treatment attenuates MASH

**Fig. 2.** Effect of BGXZW on on the levels of inflammation and autophagy related proteins and mRNA. (A and B) Western blot; (C-G) PCR; (H) mechanism. Results are expressed as the mean±SD (n=3). p<0.05 compared with the control group, p<0.05 compared with the control group, p<0.05 compared with the control group, p<0.05 compared with model group, p<0.05 compared with the model group, p<0.05 compared with model group, p<0.05 compared with the model group, p<0.05 compared with group, MCD diet and fed with pure water; p<0.05 diet and fed with PC (120 mg/kg/d); BG-L group, MCD diet and fed with high-dose BGXZW (5 g/kg/d); SW group, MCD diet and fed with SWQGT (3 g/kg/d); MCD, methionine choline deficiency; MCS, methionine and choline-sufficient; BGXZW, Bao-Gan-Xiao-Zhi-Wan; SWQGT, Si-Wei-Qing-Gan-Tang.

BGXZW attenuated MCD diet-induced MASH in rats by modulating the NF- $\kappa$ B signaling pathway and autophagy (Fig. 2H).

#### Funding

This work was supported by the Basic and Applied Basic Research Foundation of Guangdong Province (2021A1515 220185).

#### **Conflict of interest**

The authors have no conflict of interests related to this publication.

## **Author contributions**

Conceptualization, LZ, XW, LG, XZ and BZ; Data curation, LZ and JY; Formal analysis, WW and XZ; Investigation, LZ, XW, and WS; Methodology, LZ, XW, WS, JY and LG; Supervision, BZ; Writing-original draft, LZ; Writing-review & editing, LG and BZ.

### **Ethical statement**

The animal experiments were approved by the Institutional Animal Care and Use Committee of the Shenzhen People's

Hospital (No. LL-KT-2021797) and all animals received humane care.

#### **Data sharing statement**

Supplementary Materials and Methods were added in Supplementary File 1. The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

#### References

- Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010;42:320–330. doi:10.1016/j.dld.2010.01.016, PMID:202 07596.
- [2] Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, et al. MAFLD: A multisystem disease. Ther Adv Endocrinolo 2023;14: 20420188221145549. doi:10.1177/20420188221145549, PMID:36726391.
- [3] Gofton C, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD? Clin Mol Hepatol 2023;29:17–31. doi:10.3350/cmh.2022.0367, PMID:36443926.
- [4] Cataldo I, Sarcognato S, Sacchi D, Cacciatore M, Baciorri F, Mangia A, et al. Pathology of non-alcoholic fatty liver disease. Pathologica 2021;113(3):194-202. doi:10.32074/1591-951X-242, PMID:34294937.
- [5] Sanyal AJ, Williams SA, Lavine JE, Neuschwander-Tetri BA, Alexander L, Ostroff R, et al. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. J Hepatol 2023;78(4):693–703. doi:10.1016/j.jhep.2022.11.029, PMID:36528237.
- [6] Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018;67:123–133. doi:10.1002/

#### Zhou L. et al: Bao-Gan-Xiao-Zhi-Wan treatment attenuates MASH

hep.29466, PMID:28802062.

- [7] Cai FF, Bian YQ, Wu R, Sun Y, Chen XL, Yang MD, et al. Yinchenhao decoction suppresses rat liver fibrosis involved in an apoptosis regulation mechanism based on network pharmacology and transcriptomic analysis. Biomed Pharmacother 2019;114:108863. doi:10.1016/j.biopha.2019.108863, PMID: 30991286.
- [8] Xiao LY, Liang S, Ge LL, Qiu SL, Wan HQ, Wu SG, et al. Si-Wei-Qing-Gan-Tang improves non-alcoholic steatohepatitis by modulating the nuclear factor- $\kappa B$  signal pathway and autophagy in methionine and choline deficient diet-fed rats. Front Pharmacol 2020;11:530. doi:10.3389/ fphar.2020.00530, PMID:32425782. [9] Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-alcoholic stea-
- tohepatitis: a review of its mechanism models and medical treatments.

Front Pharmacol 2020;11:603926. doi:10.3389/fphar.2020.603926, PMID: 3343375. [10] Cai J, Zhang XJ, Li H. Role of innate immune signaling in non-alcoholic

- [10] Cai J, Zhang XJ, Li H. Role of innate immune signaling in non-alcoholic fatty liver disease. Trends Endocrin Met 2018;29:712–722. doi:10.1016/j. tem.2018.08.003, PMID:30131212.
  [11] Chen R, Wang Q, Song S, Liu F, He B, Gao X. Protective role of autophagy in methionine-choline deficient diet-induced advanced nonalcoholic steatohepatitis in mice. Eur J Pharmacol 2016;770:126–133. doi:10.1016/j. ejphar.2015.11.012, PMID:26593434.
  [12] Wang Y, Nie H, Zhao X, Qin Y, Gong X. Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the P13K/AKT and Ras/Raf/MEK/ERK pathways. BMC Cancer 2016;16:742. doi:10.1186/s12885-016-2767-2, PMID:27654866.